PL
DGX icon

Pluribus Labs’s Quest Diagnostics DGX Stock Holding History

Pluribus Labs’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$282K Buy
+2,122
New +$289K 0.51% 65

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Pluribus Labs's DGX Position: Q2 2022 in Review

Pluribus Labs opened a new position in Quest Diagnostics (DGX) in Q2 2022: 2,122 shares worth $282K. The stake represents 0.51% of the portfolio and ranks #65 among its holdings.

851 funds tracked by Wall St. Rank hold DGX as of Q2 2022.

  • Pluribus Labs held 2,122 shares of Quest Diagnostics worth $282K as of Q2 2022.
  • Quest Diagnostics was a new Pluribus Labs position in Q2 2022.
  • Quest Diagnostics made up 0.51% of Pluribus Labs's portfolio in Q2 2022, its #65 holding.
  • 851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2022.

Based on Pluribus Labs's 13F filing for Q2 2022, filed 12 Aug 2022.